<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE paragraph PUBLIC "-//IFRS//DTD DITA Paragraph//EN" "../../../DocTypes/com.ifrs.doctype/dtd/paragraph.dtd"><paragraph id="IFRS03_IE91" principles="no"><paranum class="- topic/title paragraph/paranum "/><titlealts><navtitle>IE91</navtitle></titlealts><prolog><data name="standard_number" value="IFRS&#xa0;3"/><data name="paranum" value="IE91"/></prolog><body><p id="IFRS03_IE91_P0001" outputclass="keep_with_next">Purchaser elects to apply the optional       concentration test set out in <xref href="IFRS03_B7B.dita">paragraph B7B</xref> and concludes that:</p><ol outputclass="static" type="lower-alpha"><li id="IFRS03_IE91_a"><li_value>(a)</li_value><p>Project 1 and Project 2 are identifiable intangible assets that           would each be recognised and measured as a separate identifiable asset in a business           combination.</p></li><li id="IFRS03_IE91_b"><li_value>(b)</li_value><p>Project 1 and Project 2 are not similar identifiable assets           because significantly different risks are associated with managing and creating outputs           from each asset. Each project has significantly different risks associated with           developing, completing and marketing the compound to customers. The compounds are intended           to treat significantly different medical conditions, and each project has a significantly           different potential customer base.</p></li><li id="IFRS03_IE91_c"><li_value>(c)</li_value><p>consequently, the fair value of the gross assets acquired is           not substantially all concentrated in a single identifiable asset or group of similar           identifiable assets. Therefore, Purchaser assesses whether the set meets the minimum           requirements to be considered a business in accordance with <xref href="IFRS03_gB8-B11.dita">paragraphs B8&#x2013;B12D</xref>.</p></li></ol></body></paragraph>